Abstract:Purpose of Study Thrombocytopenia during chemotherapy is not always due to myelosuppression. We report an unusual case of isolated acute thrombocytopenia after oxaliplatin and irinotecan administration. We reviewed 11 reported cases to better understand the nature of the presentation and variability in response to treatment. Case Report Patient is a 63 year old female with metastatic colon cancer treated with palliative chemotherapy with FOLFOX. Follwing her 14th cycle she had an episode of acute drop in platelet count to 8,000/microliter. Peripheral smear revealed no evidence of thrombotic microangiopathy. She was managed with supportive platelet transfusions with slow recovery of platelet count. Subsequently she was treated with second line chemotherapy with FOLFIRI. Following the first cycle of Irinotecan, she again had a catastrophic drop in platelets from 136,000/microliter to 6,000/microliter within 10 hours. Due to this recurrent episode, a drug mediated thrombocytopenia was suspected and work up was initiated. She was initially treated with dexamethasone without a significant response. Platelet count normalized after 7 days with supportive platelet transfusions. Methods Used Blood was tested for drug dependent platelet antibodies by Flow Cytometry at the Platelet and Neutrophil Immunology Laboratory at the Blood Center of Wisconsin. Summary of Results The patient's serum showed evidence of drug dependent platelet antibodies to both oxaliplatin and irinotecan. Conclusions Drug mediated immune thrombocytopenia is not uncommon. Time to severe acute thrombocytopenia and platelet recovery time varied post exposure of the drug. It is unclear whether steroid or IVIG administration had any effect on the platelet recovery time. Recovery from thrombocytopenia was observed in all 11 cases after the discontinuation of the insulting agent. Confirmation of the presence of drug dependent platelet antibodies against the chemotherapeutic agent by flow cytometry essential for diagnosis. This would be the first reported case of acute thrombocytopenia to two different chemotherapeutic agents in the same patient. Whether the reaction is two different mechanisms or if there is a cross reactivity between Oxaliplatin and Irinotecan has yet to be investigated.

Oxaliplatin-induced transient ischemic attack (TIA): A rare presentation

Digital ischaemia and necrosis from oxaliplatin

Dose dependent slurred speech and laryngopharyngeal dysesthesia due to oxaliplatin

Oxaliplatin-related Portal Hypertension Complicated with Esophageal Varices and Refractory Massive Ascites

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

Oxaliplatin-Induced Immune Thrombocytopenia in a Patient with Pancreatic Cancer

Oxaliplatin-associated shock in stage III colorectal cancer patients: real-world evidence in Taiwan

Hypersensitivity Reactions to oxaliplatin: incidence and management

P8: CHEMOTHERAPY INDUCED IMMUNE THROMBOCYTOPENIA-AN ENTITY TO KEEP IN MIND!

Lower-extremity deep vein thrombosis induced by oxaliplatin and capecitabine chemotherapy: A case report

Acute Encephalopathy Following Arsenic Trioxide for Metastatic Urothelial Carcinoma

Case Report: Oxaliplatin-Induced Third-Degree Atrioventricular Block: First Discovery of an Important Side-Effect

Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database

Case Report: Oxaliplatin-induced Idiopathic Non-Cirrhotic Portal Hypertension: a Case Report and Literature Review

Oxaliplatin: results in colorectal carcinoma

A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia

Oxaliplatin induced hepatic sinusoidal obstruction syndrome:prevention and treatment

Oxaliplatin-induced immune pancytopenia:A report of 1 case and literature review

S4296 Oxaliplatin-Induced Non-Cirrhotic Portal Hypertension

Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice

Differentiating between Laryngopharyngeal Dysesthesia and Hypersensitivity Reactions to Oxaliplatin and Addressing Dyspnea: 2 Case Reports